Veronica Conca

Also affiliated with Azienda Ospedaliera Universitaria Pisana

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial”.

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(22)00274-1

N/A

0.841DataRank · unranked

272 citations

Daniele Rossini, Filippo Pietrantonio, Aurélie Catteau, Lisa Salvatore, Sara Lonardi +32 more

Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1379

N/A

0DataRank · unranked

13 citations

Yoshiaki Nakamura, Rona Yaeger, Sara Lonardi, Chiara Cremolini, Élena Elez +17 more